High proportion of potential candidates for immunotherapy in a Chilean cohort of gastric cancer patients: results of the FORCE1 study

Simple item page
dc.article.number1275
dc.catalogadorpva
dc.contributor.authorCordova-Delgado, Miguel
dc.contributor.authorMauricio P. Pinto
dc.contributor.authorIgnacio N. Retamal
dc.contributor.authorMatías Muñoz-Medel
dc.contributor.authorMaría Loreto Bravo
dc.contributor.authorMaría F. Fernández
dc.contributor.authorBetzabé Cisternas
dc.contributor.authorSebastián Mondaca
dc.contributor.authorCésar Sanchez
dc.contributor.authorHector Galindo
dc.contributor.authorBruno Nervi
dc.contributor.authorCarolina Ibáñez
dc.contributor.authorFrancisco Acevedo
dc.contributor.authorJorge Madrid
dc.contributor.authorJosé Peña
dc.contributor.authorErica Koch
dc.contributor.authorMaria José Maturana
dc.contributor.authorDiego Romero
dc.contributor.authorNathaly de la Jara
dc.contributor.authorJaviera Torres
dc.contributor.authorManuel Espinoza
dc.contributor.authorCarlos Balmaceda
dc.contributor.authorYuwei Liao
dc.contributor.authorZhiguang Li
dc.contributor.authorMatías Freire
dc.contributor.authorValentina Gárate-Calderón
dc.contributor.authorJavier Cáceres
dc.contributor.authorGonzalo Sepúlveda-Hermosilla
dc.contributor.authorRodrigo Lizana
dc.contributor.authorLiliana Ramos
dc.contributor.authorRocío Artigas
dc.contributor.authorEnrique Norero
dc.contributor.authorFernando Crovari
dc.contributor.authorRicardo Armisén
dc.contributor.authorAlejandro H. Corvalán
dc.contributor.authorGareth I. Owen
dc.contributor.authorMarcelo Garrido
dc.date.accessioned2024-01-19T18:21:50Z
dc.date.available2024-01-19T18:21:50Z
dc.date.issued2019
dc.description.abstractGastric cancer (GC) is a heterogeneous disease. This heterogeneity applies not only to morphological and phenotypic features but also to geographical variations in incidence and mortality rates. As Chile has one of the highest mortality rates within South America, we sought to define a molecular profile of Chilean GCs (ClinicalTrials.gov identifier: NCT03158571/(FORCE1)). Solid tumor samples and clinical data were obtained from 224 patients, with subsets analyzed by tissue microarray (TMA; n = 90) and next generation sequencing (NGS; n = 101). Most demographic and clinical data were in line with previous reports. TMA data indicated that 60% of patients displayed potentially actionable alterations. Furthermore, 20.5% were categorized as having a high tumor mutational burden, and 13% possessed micro-satellite instability (MSI). Results also confirmed previous studies reporting high Epstein-Barr virus (EBV) positivity (13%) in Chilean-derived GC samples suggesting a high proportion of patients could benefit from immunotherapy. As expected, TP53 and PIK3CA were the most frequently altered genes. However, NGS demonstrated the presence of TP53, NRAS, and BRAF variants previously unreported in current GC databases. Finally, using the Kendall method, we report a significant correlation between EBV+ status and programmed death ligand-1 (PDL1)+ and an inverse correlation between p53 mutational status and MSI. Our results suggest that in this Chilean cohort, a high proportion of patients are potential candidates for immunotherapy treatment. To the best of our knowledge, this study is the first in South America to assess the prevalence of actionable targets and to examine a molecular profile of GC patients.
dc.fechaingreso.objetodigital2024-05-06
dc.fuente.origenORCID-ene24
dc.identifier.doi10.3390/cancers11091275
dc.identifier.urihttp://dx.doi.org/10.3390/cancers11091275
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/80810
dc.information.autorucEscuela de Medicina; Acevedo Claros, Francisco Nicolas; 0000-0003-3482-7746; 119540
dc.issue.numero9
dc.language.isoen
dc.nota.accesoContenido completo
dc.revistaCancers
dc.rightsacceso abierto
dc.subjectGastric cancer
dc.subjectGastric adenocarcinoma
dc.subjectCancer subtypes
dc.subjectPrognosis
dc.subjectSurvival
dc.subjectMolecular
dc.subject.ddc610
dc.subject.deweyMedicina y saludes_ES
dc.titleHigh proportion of potential candidates for immunotherapy in a Chilean cohort of gastric cancer patients: results of the FORCE1 study
dc.typeartículo
dc.volumen11
sipa.codpersvinculados119540
sipa.trazabilidadORCID;2024-01-08
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
cancers-11-01275-v2.pdf
Size:
1.27 MB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Artículos de revistas